{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:19:12Z","timestamp":1791609552540,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Ged\u00e4chtnisambulanzen in Deutschland stehen aufgrund zunehmender Patientenzahlen und erster verf\u00fcgbarer krankheitsmodifizierender Therapien f\u00fcr die Alzheimer-Krankheit vor gro\u00dfen Herausforderungen. Es m\u00fcssen Kapazit\u00e4ten f\u00fcr Beratung, biomarkerbasierte Diagnostik, Therapien und Kontrolluntersuchungen geschaffen werden, sodass eine Anpassung der Arbeitsabl\u00e4ufe notwendig ist. \u201eValue-based healthcare\u201c (VBHC) bietet die Chance, Optimierungen so zu gestalten, dass der patientenbezogene Nutzen neben Kosten- und Effizienzgesichtspunkten im Mittelpunkt steht.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Dieses Projekt wendet VBHC erstmals auf Ged\u00e4chtnisambulanzen an, um nach seiner zentralen Formel (\u201evalue\u202f=\u2009outcome\/costs\u201c) ein besseres Outcome f\u00fcr Patienten und Angeh\u00f6rige bei einem effizienteren Einsatz bestehender Ressourcen (\u201ecosts\u201c) zu erreichen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>Durch eine erste Befragung von Patienten und Angeh\u00f6rigen wurden wesentliche Aspekte in Bezug auf VBHC erfasst und hierauf basierend bestehende Arbeitsabl\u00e4ufe modifiziert. Diese Modifikationen wurden durch eine zweite Befragung und Analysen vor allem prozessorientierter Aspekte evaluiert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Bereits bei der ersten Befragung bestand eine generelle Zufriedenheit mit der Vorstellung in der Ged\u00e4chtnisambulanz. Als zentraler Kritikpunkt erwies sich aber die Dauer des Diagnostikprozesses. Nach Modifikation konnten Dauer und Umfang der Diagnostik reduziert werde. Die Befragten bewerteten die modifizierten Abl\u00e4ufe besser und Ressourcen wurden eingespart.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>In unserer Ambulanz wurde durch eine erh\u00f6hte Behandlungszufriedenheit (\u201eoutcome\u201c) bei verringerten Personalbindungszeiten (\u201ecosts\u201c) eine Verbesserung im Sinne von VBHC erzielt. Dieses Modell kann anderen Ged\u00e4chtnisambulanzen als Vorbild f\u00fcr die Entwicklung einer patientenzentrierteren und effizienteren Versorgung dienen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00115-025-01903-w","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:59:43Z","timestamp":1763377183000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimierung der Arbeit von Ged\u00e4chtnisambulanzen unter Gesichtspunkten von \u201evalue-based healthcare\u201c\u00a0\u2013 ein Ansatz aus dem Zentrum f\u00fcr Ged\u00e4chtnisst\u00f6rungen der Uniklinik K\u00f6ln","Optimization of the work of outpatient memory clinics under aspects of value-based healthcare\u2014An approach from the Center for Memory Disorders of the University Hospital Cologne"],"prefix":"10.1007","volume":"97","author":[{"given":"Anna","family":"Sch\u00f6nberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Katrin","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Simandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ttler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1903_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/TRC2.12465","author":"J Cummings","year":"2024","unstructured":"Cummings\u00a0J, Zhou\u00a0Y, Lee\u00a0G et\u00a0al (2024) Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement. https:\/\/doi.org\/10.1002\/TRC2.12465","journal-title":"Alzheimers Dement"},{"key":"1903_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-020-00659-6","author":"DB Dibenedetti","year":"2020","unstructured":"Dibenedetti\u00a0DB, Slota\u00a0C, Wronski\u00a0SL et\u00a0al (2020) Assessing what matters most to patients with or at risk for Alzheimer\u2019s and care partners: a\u00a0qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/S13195-020-00659-6","journal-title":"Alzheimers Res Ther"},{"key":"1903_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMOA2212948","volume":"388","author":"H van Dyck","year":"2023","unstructured":"van Dyck\u00a0H, Swanson\u00a0C, Aisen\u00a0P et\u00a0al (2023) Lecanemab in Early Alzheimer\u2019s Disease. N\u00a0Engl J Med 388:142\u2013143. https:\/\/doi.org\/10.1056\/NEJMOA2212948","journal-title":"N Engl J Med"},{"key":"1903_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737167.2023.2136168","volume":"23","author":"JFH Eijsink","year":"2023","unstructured":"Eijsink\u00a0JFH, Fabian\u00a0AM, Vervoort\u00a0JPM et\u00a0al (2023) Value-based health care in Western countries: a\u00a0scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions. Expert Rev Pharmacoecon Outcomes Res 23:1\u201313. https:\/\/doi.org\/10.1080\/14737167.2023.2136168","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1903_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, McHugh\u00a0PR (1975) \u201cMini-mental state\u201d. A\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res 12:189\u2013198. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"1903_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1742395309348072","volume":"5","author":"PC Gugiu","year":"2009","unstructured":"Gugiu\u00a0PC, Coryn\u00a0C, Clark\u00a0R, Kuehn\u00a0A (2009) Development and evaluation of the short version of the patient assessment of chronic illness care instrument. Chronic Illn 5:268\u2013276. https:\/\/doi.org\/10.1177\/1742395309348072","journal-title":"Chronic Illn"},{"key":"1903_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ALZ.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson\u00a0A, Norton\u00a0N, Fast\u00a0T et\u00a0al (2023) Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement 19:658\u2013670. https:\/\/doi.org\/10.1002\/ALZ.12694","journal-title":"Alzheimers Dement"},{"key":"1903_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/S00115-020-01007-7","volume":"92","author":"L Hausner","year":"2021","unstructured":"Hausner\u00a0L, Fr\u00f6lich\u00a0L, von Arnim\u00a0CAF et\u00a0al (2021) Ged\u00e4chtnisambulanzen in Deutschland \u2013 strukturell organisatorische Voraussetzungen und Aufgabenfelder. Nervenarzt 92:708\u2013715. https:\/\/doi.org\/10.1007\/S00115-020-01007-7","journal-title":"Nervenarzt"},{"key":"1903_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/S11136-011-9903-X","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman\u00a0M, Gudex\u00a0C, Lloyd\u00a0A et\u00a0al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/S11136-011-9903-X","journal-title":"Qual Life Res"},{"key":"1903_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S13195-024-01441-8","author":"LS Honig","year":"2024","unstructured":"Honig\u00a0LS, Sabbagh\u00a0MN, van Dyck\u00a0CH et\u00a0al (2024) Updated safety results from phase\u00a03 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/S13195-024-01441-8","journal-title":"Alzheimers Res Ther"},{"key":"1903_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.14283\/JPAD.2022.22","volume":"9","author":"F Jessen","year":"2022","unstructured":"Jessen\u00a0F, Georges\u00a0J, Wortmann\u00a0M, Benham-Hermetz\u00a0S (2022) What matters to patients with Alzheimer\u2019s disease and their care partners? Implications for understanding the value of future interventions. J\u00a0Prev Alzheimers Dis 9:550\u2013555. https:\/\/doi.org\/10.14283\/JPAD.2022.22","journal-title":"J Prev Alzheimers Dis"},{"key":"1903_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMOA2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun\u00a0MA, Lo\u00a0AC, Duggan Evans\u00a0C et\u00a0al (2021) Donanemab in Early Alzheimer\u2019s Disease. N\u00a0Engl J Med 384:1691\u20131704. https:\/\/doi.org\/10.1056\/NEJMOA2100708","journal-title":"N Engl J Med"},{"key":"1903_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/BJP.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery\u00a0SA, Asberg\u00a0M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382\u2013389. https:\/\/doi.org\/10.1192\/BJP.134.4.382","journal-title":"Br J Psychiatry"},{"key":"1903_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/GERONJ\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer\u00a0RI, Kurosaki\u00a0TT, Harrah\u00a0CH et\u00a0al (1982) Measurement of functional activities in older adults in the community. J\u00a0Gerontol 37:323\u2013329. https:\/\/doi.org\/10.1093\/GERONJ\/37.3.323","journal-title":"J Gerontol"},{"key":"1903_CR15","volume-title":"Redefining health care: creating value-based competition on results","author":"M Porter","year":"2006","unstructured":"Porter\u00a0M, Teisberg\u00a0E (2006) Redefining health care: creating value-based competition on results. Harvard business press"},{"key":"1903_CR16","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMP1011024","volume":"363","author":"ME Porter","year":"2010","unstructured":"Porter\u00a0ME (2010) What is value in health care? N\u00a0Engl J Med 363:2477\u20132481. https:\/\/doi.org\/10.1056\/NEJMP1011024","journal-title":"N Engl J Med"},{"key":"1903_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMP1511701","volume":"374","author":"ME Porter","year":"2016","unstructured":"Porter\u00a0ME, Larsson\u00a0S, Lee\u00a0TH (2016) Standardizing patient outcomes measurement. N\u00a0Engl J Med 374:504\u2013506. https:\/\/doi.org\/10.1056\/NEJMP1511701","journal-title":"N Engl J Med"},{"key":"1903_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-200484","volume":"80","author":"A Rostamzadeh","year":"2021","unstructured":"Rostamzadeh\u00a0A, Schwegler\u00a0C, Gil-Navarro\u00a0S et\u00a0al (2021) Biomarker-based risk prediction of Alzheimer\u2019s disease dementia in mild cognitive impairment: psychosocial, ethical, and legal aspects. J\u00a0Alzheimers Dis 80:601\u2013617. https:\/\/doi.org\/10.3233\/JAD-200484","journal-title":"J Alzheimers Dis"},{"key":"1903_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S12913-022-07489-2","author":"DJ van Staalduinen","year":"2022","unstructured":"van Staalduinen\u00a0DJ, van den Bekerom\u00a0P, Groeneveld\u00a0S et\u00a0al (2022) The implementation of value-based healthcare: a\u00a0scoping review. BMC Health Serv Res. https:\/\/doi.org\/10.1186\/S12913-022-07489-2","journal-title":"BMC Health Serv Res"},{"key":"1903_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen\u00a0CE, Verberk\u00a0IMW, Thijssen\u00a0EH et\u00a0al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"Lancet Neurol"},{"key":"1903_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/J.DADM.2018.12.003","volume":"11","author":"C Tochel","year":"2019","unstructured":"Tochel\u00a0C, Smith\u00a0M, Baldwin\u00a0H et\u00a0al (2019) What outcomes are important to patients with mild cognitive impairment or Alzheimer\u2019s disease, their caregivers, and health-care professionals? A\u00a0systematic review. Alzheimers Dement 11:231\u2013247. https:\/\/doi.org\/10.1016\/J.DADM.2018.12.003","journal-title":"Alzheimers Dement"},{"key":"1903_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1982","unstructured":"Yesavage\u00a0JA, Brink\u00a0TL, Rose\u00a0TL et\u00a0al (1982) Development and validation of a\u00a0geriatric depression screening scale: a\u00a0preliminary report. J\u00a0Psychiatr Res 17:37\u201349. https:\/\/doi.org\/10.1016\/0022-3956(82)90033-4","journal-title":"J Psychiatr Res"},{"key":"1903_CR23","unstructured":"S3-Leitlinie Demenzen (Living Guideline). https:\/\/app.magicapp.org\/#\/guideline\/nYPaxL (AWMF-Reg.-Nr. 038-013)"},{"key":"1903_CR24","unstructured":"European Medicines Agency (EMA) Leqembi recommended for treatment of early Alzheimer\u2019s disease. https:\/\/www.ema.europa.eu\/en\/news\/leqembi-recommended-treatment-early-alzheimers-disease"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01903-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01903-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01903-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:10:41Z","timestamp":1772460641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-025-01903-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1007\/s00115-025-01903-w","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Sch\u00f6nberger, A.\u00a0Steinmetz und F.\u00a0Simandi geben an, dass kein Interessenkonflikt besteht.A.-K.\u00a0Schild hat zwischen 2022 und 2025 Honorare f\u00fcr Vortr\u00e4ge erhalten von: Novo Nordisk Pharma GmbH und Lilly Deutschland GmbH. G.S.\u00a0Benson hat in 2022 Honorare f\u00fcr Beratung und Vortr\u00e4ge erhalten von Roche Pharma AG. L.\u00a0Hausner erhielt Honorare f\u00fcr Vortr\u00e4ge von MedTriX (2021, 2022 und 2023), Medfora (2021) und Roche (2021) und Roche-Beratert\u00e4tigkeit (2022). M.\u00a0Sch\u00f6ttler ist Mitarbeiter der Roche Pharma AG und besitzt Aktien der F. Hoffmann-La Roche AG. B.\u00a0Hennig steht in einem Besch\u00e4ftigungsverh\u00e4ltnis mit der Roche Diagnostics Deutschland GmbH und besitzt Aktien der F.\u00a0Hoffmann-La Roche AG. A.\u00a0Knudsen stand von 2023\u20132024 in einem Besch\u00e4ftigungsverh\u00e4ltnis bei der Roche Pharma AG und besa\u00df in diesem Zeitraum Aktien der F. Hoffmann-La Roche AG. Er war von 2024\u20132025 bei der Novartis Pharma GmbH und ist seit 2025 bei der Roche Diagnostics Deutschland GmbH angestellt. F.\u00a0Maier hat zwischen 2022 und 2025 1.\u00a0Honorare f\u00fcr Vortr\u00e4ge erhalten von: Novo Nordisk Pharma GmbH. 2.\u00a0Honorare f\u00fcr Advisory Boards erhalten: Johnson & Johnson und Lilly Deutschland GmbH. L.\u00a0Fr\u00f6lich hat zwischen 2020 und 2025 Honorare f\u00fcr Beratung und Vortr\u00e4ge erhalten von: Biogen, BioVie, Eli Lilly, Eisai, GE Healthcare, Grifols, Janssen, Neurimmune, Noselab, NovoNordisk, Roche, TauRX, Schwabe, Medscape, Medfora und FOMF sowie institutionelle F\u00f6rderung von Hoffmann-La Roche. Zudem steht er in Verbindung zur German Society of Psychiatry, Psychotherapy and Nervous Diseases (Guideline committee), European Alzheimer Disease Consortium, German Network of Memory Clinics, Alzheimer Europe, Alzheimer Society Baden-W\u00fcrttemberg. F.\u00a0Jessen hat zwischen 2022 und 2025 Honorare f\u00fcr Beratung und Vortr\u00e4ge erhalten von: Abbvie, AC immune, Biogen, Eli Lilly, Eisai, GE Healthcare, Grifols, Janssen-Cliag und Roche Pharma sowie institutionelle Forschungsf\u00f6rderung von Roche Pharma und Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}